This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the decades since its identification in 1989, advances in clinicalresearch for new Hepatitis C therapies and the introduction of direct-acting antiviral agents (DAAs) have led to viral eradication in more than 98% of patients, resulting in HCV crossing from manageable to being the first curable , chronic viral infection.
2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. 7 Recent clinical studies highlight promising developments in c-MET-targeting ADCs for NSCLC.
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Stem cell transplants primarily help the immuneresponse through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.”
We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. Generally, IO has been focused on harnessing the anti-tumour activity of certain cancer-fighting T-cells , a key cell type involved in the adaptive immune defense system.
Development of cell and gene therapies is growing rapidly, given the major advances in genomic technologies and increasing scientific understanding of genetic regulation and immunology. This blog will outline three characteristics of a successful nonclinical program to support entry into clinical trials for a cell or gene therapy product.
As medical understanding grew, so did the sophistication of the therapies. These targeted therapies revolutionized treatment, offering relief to severe cases by specifically addressing the underlying immuneresponses causing the disease.
The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinicalresearch , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.
The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinicalresearchers to discuss the latest advancements and challenges in oncology research. Check out this webinar on navigating the landscape of oncology clinical trials.
Topical Treatments and Light Therapy Initially, treatments focused on topical applications and light therapy. The Current Landscape of Vitiligo Treatment Today, the treatment of vitiligo is more personalized and sophisticated, thanks to advancements in medical research and technology.
Radiation therapy. Immunosuppressive therapy may also be used to treat bullous pemphigoid. This therapy uses drugs such as azathioprine to suppress your body’s immuneresponse. Immunosuppressive therapy is typically only used when other treatments haven’t worked or your symptoms are severe.
Fortunately, advances in clinicalresearch are providing hope for better treatments and outcomes. With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world.
With ongoing research and clinical trials , institutions like Olympian ClinicalResearch are at the forefront of finding innovative treatment options. For more severe cases, systemic medications, including newer biologics that target immuneresponses, are used. What is Pediatric Plaque Psoriasis?
HS is believed to develop due to an immuneresponse that generates too much inflammation. People with HS may have an overactive immune system, which causes their bodies to overreact to the presence of a blocked hair follicle. ClinicalResearch on Hidradenitis Suppurativa. It’s also not caused by poor hygiene.
We now have a pipeline of undisclosed therapeutic partnerships nearing clinicalresearch. The experience in antibody discovery shared by FJB and IONTAS, together with their unique library of target binders, makes them ideal partners as we focus on successfully progressing these transformational therapies to patients in need.”.
Both Jerry and Jeff have proven and successful track records in the design and execution of early and late-stage clinical trials that have evaluated novel immunetherapies. The backbone of NexImmune’s approach is its proprietary Artificial Immune Modulation (AIM TM ) nanoparticle technology platform.
These markers can inform treatment response and help reduce patient radiation exposure by reducing the need for repeated imaging assessments in clinical trials.
The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. It was co-sponsored by Merck and Bayer, conducted with the scientific oversight of the Canadian VIGOUR Centre and the Duke ClinicalResearch Institute.
Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and they are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. NBTXR3 is injected one time, directly into solid tumors.
The data demonstrated the vaccine elicited a combined adaptive humoral and cellular immuneresponse and also provided insights into the composite nature of BNT162b2-induced T-cell immunity. eTrueNorth is actively recruiting COVID-19-positive patients about potential participation in the NIH’s ACTIV-2 clinicalresearch trial.
This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy.
NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immuneresponse.
While other regimens have shown similar promising results, the authors note that in low and middle income countries this simple and low-cost treatment may be suitable as a maintenance therapy in high-risk LGG patients. Gauthier Bouche & Pan Pantziarka Gauthier Bouche (MD) is Director of ClinicalResearch at the Anticancer Fund.
This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America ClinicalResearch Organization (CRO), based in Sao Paulo City, Brazil. The clinical data from this trial is expected to available by the end of this year. Brazil has reported almost 5.5M
We’re excited to be collaborating with Tiziana to support the development of a novel, oral therapy that could provide Crohn’s patients with another option in their repertoire of treatments to combat this devastating disease.”. Parexel is focused on supporting the development of innovative therapies to improve patient health.
“This study suggests that maybe we could predict or diagnose depression based on inflammatory scores,” said Samara Huckvale, an undergraduate at Columbia University working in the laboratory of UT Southwestern professor Sherwood Brown, senior author of both papers and professor of psychiatry and vice chair for clinicalresearch at UTSW. “Or
Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy. in these patients.
Earlier this year, the researchers shared their first translational results, describing the immune cell response underlying colon inflammation in patients undergoing ICI therapy. These are home-run, breakthrough therapies, and quite an amazing success story. How did you go about launching this effort?
Fortunately, advances in clinicalresearch are providing hope for better treatments and outcomes. With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world.
Today, scientists would halt clinicalresearch on drugs with these properties, but back then, many researchers put stock in the “magic bullet” theory proposed by Paul Ehrlich , a German biologist. Interferon gamma release assays pick up an immuneresponse to the infection. A sputum test stain for M.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content